Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) has tapped Ellen Lintal as its new chief accounting officer.
Lintal joined the Florida biopharmaceutical group in 2018 as a vice-president of finance and control.
READ: Hemispherx Biopharma kicks off Phase 1 trial to treat advanced breast cancer with key drug Ampligen
Prior to coming on board at Hemispherx, Lintal spent a decade at an undisclosed international non-profit organization, where she served as a chief financial officer and a senior vice-president of finance and control. Her career also includes accounting experience while working for Corning, the Carlisle Companies and AGY.
“Ms. Lintal has done a superb job since arriving at Hemispherx and will make an excellent chief accounting officer,” said CEO Thomas Equels in a statement.
Hemispherx is focusing its research and development efforts on advancing its flagship cancer drug Ampliglen as an immuno-therapy. The drug is currently being evaluated to treat nine different types of tumors.
Contact Ellen Kelleher at [email protected]